MétaCan
Menu
← Back to cohort

Amylin receptor agonism protects against metabolic side effects of acute olanzapine

2023· article· en· W4378648413 on OpenAlexaffabout
Kyle D. Medak, Stewart Jeromson, Annalaura Belluci, Meagan Arbeau, David C. Wright

Bibliographic record

VenuePhysiology · 2023
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsUniversity of Guelph
Fundersnot available
KeywordsLiraglutideOlanzapineAmylinMedicineEndocrinologyInternal medicineDyslipidemiaGlucose homeostasisInsulin resistancePharmacologyInsulinDiabetes mellitusType 2 diabetesSchizophrenia (object-oriented programming)

Abstract

fetched live from OpenAlex

Olanzapine is a second-generation antipsychotic (SGA) used in the treatment of schizophrenia and several on- and off-label conditions. While effective in reducing psychoses, acute olanzapine treatment causes rapid hyperglycemia, insulin resistance, and dyslipidemia and these perturbations are linked to an increased risk of developing cardiometabolic disease. Increases in glucagon are central to the metabolic side effects of olanzapine. Amylin receptor activation has been shown to reduce circulating glucagon but it is unclear if targeting amylin signaling would be an effective approach to lessen olanzapine-induced hyperglycemia alone or as an adjunct with other glucose lowering medications such as glucagon-like peptide-1 (GLP1) receptor agonist liraglutide. The purpose of this study was to 1) determine if treatment with recombinant amylin or the amylin receptor agonist pramlintide is sufficient to protect against acute olanzapine-induced impairments in glucose and lipid homeostasis and 2) if there are synergistic effects of combining pramlintide and liraglutide. We hypothesized that amylin and pramlintide would confer protection against olanzapine-induced perturbations in glucose homeostasis and that these effects would be additive with liraglutide. We found that pramlintide co-treatment lowered olanzapine-induced increases in glucagon:insulin. There was an additive effect of pramlintide and liraglutide in protecting against olanzapine-induced hyperglycemia and a synergistic effect on markers of dyslipidemia. Our findings provide evidence that pramlintide, while moderately protective against some aspects of olanzapine-induced metabolic dysfunction, can be used to enhance other interventions which protect against olanzapine-induced hyperglycemia. This research was supported by a Project Grant (PJT 159538) from the Canadian Institutes of Health Research to DCW. KDM was supported by a Postgraduate Scholarship from the Natural Sciences and Engineering Research Council (NSERC) of Canada. This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.008

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.261
Teacher spread0.251 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes2
Has abstractyes

Explore more

Same venuePhysiology→Same topicDiabetes Treatment and Management→French-language works237,207→